Clinical Trials

Taletrectinib is currently being evaluated in multiple Phase 2 clinical trials in first and second-line ROS1-positive NSCLC. The global Phase 2 trial TRUST-II is actively enrolling patients. The China Phase 2 trial TRUST has enrolled more than 100 patients. Two Phase 1 trials, one conducted in the US and the other study in Japan, have been successfully completed.

Taletrectinib for ROS1 fusion-positive NSCLC

Trial Title Trial Number Stage Status Publication

Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC (TRUST-II)

NCT04919811

Phase 2, Global (US, Japan, Korea, Europe, Canada, and China )

Recruiting

To be released

A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene (TRUST)

NCT04395677

Phase 2, China

Recruiting

CSCO 2021 preliminary results, cutoff date Jun 16, 2021

ASCO 2021, preliminary results, cutoff date Apr 8, 2021

Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors

NCT02675491

Phase 1, Japan

Completed

JTO 2021, pooled analysis of the two Phase 1 studies

CCR 2020, US phase 1 study

Oncotarget 2018, Japan phase 1 study

A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b

NCT02279433

Phase 1, US

Completed

JTO 2021, pooled analysis of the two Phase 1 studies

CCR 2020, US phase 1 study

Oncotarget 2018, Japan phase 1 study

Contact Us

For questions about ongoing clinical trials, please contact trials@anhearttherapeutics.com.

“Taletrectinib (AB106/DS6051b) has shown meaningful clinical activity in patients with advanced ROS1+ NSCLC who are ROS1 TKI-naive or crizotinib-refractory and a manageable safety profile.”

from Jan 2021, JTO Clinical and Research Reports.

still image of video, click to play.

Dr. Misako Nagasaka speaks about taletrectinib data, Nov 2021